Brachytherapy

What is it?

Brachytherapy delivers radiation internally. There are 2 main types: low-dose seed implant brachytherapy and high-dose rate brachytherapy (HDR).

Low-dose seed implant brachytherapy
  • Usually recommended to men with lowergrade cancers that are contained within the prostate gland.
  • Between 80 and 100 radioactive seeds, the size of a grain of rice, are implanted directly into the prostate.
  • Each seed releases low-energy level radiation steadily over several months.
HDR
  • Reserved for patients with high-grade cancers.
  • High-dose radiation is received through approximately 15 needles in the prostate, concentrating on the cancerous areas.
What is done?

Low-dose seed implant brachytherapy
  • The seeds are inserted through the skin in the perineum.
  • Procedure is performed under either general or spinal anesthesia and lasts approximately 1 hour.
HDR
  • Under anesthesia, approximately 10–15 needles are inserted through the perineum.
  • These needles are wired to the radiation source that delivers a high radiation dose to the prostate.
  • The needles are then removed.
  • The treatment takes 10–20 minutes.
What to expect?

Low-dose seed implant brachytherapy
  • A catheter may be used for a short time for urine drainage.
HDR
  • Often preceded or followed by a few weeks of external beam radiation.
  • Sometimes HDR treatments are given over a few days and the external beam radiation is not needed.
Side effects and risks
  • Side-effects of brachytherapy are similar to those of external beam radiation.
  • Brachytherapy differs slightly in the following ways:
    • Dominant short-term side-effect is irritation to the bladder and urethra
    • Acute urinary r etention may develop
    • Bowel irritation is relatively uncommon
    • Side effects may last months
Long term side effects
  • Very rare risk of incontinence of urine or chronic urinary obstruction (both less than 5%).
  • Erectile Dysfunction may occur, though many men will be able to achieve an erection with the use of prescription medication.

For more information and support:





Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
RFP: Content Development and Delivery of an Accredited Electronic Continuing Medical Education Course for Prostate Cancer Specialists

Prostate Cancer Canada invites applications from service providers interested in the development, promotion and delivery of an accredited electronic Continuing Medical Education course targeting prostate cancer specialists, including urologists.
More

Prostate Cancer Canada announces new President and CEO

Toronto, December 21, 2017 – After five successful years under the leadership and guidance of outgoing President and CEO, Rocco Rossi, Prostate Cancer Canada (PCC) is excited to announce the appointment of a most worthy successor in Peter Coleridge, past national CEO of the Canadian Mental Health Association and current national President and CEO of Big Brothers Big Sisters of Canada.
More

Université de Sherbrooke Researchers’ Findings Published in Cancer Research

Sherbrooke, November 16, 2017 – Prostate cancer, the most common cancer in men, affects one out of seven Canadian men.
More


Click here for news archive